melanoma
Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.
Biochemotherapy with low doses of subcutaneous <span class="gene" id="16131448-0-47-60">interleukin-2</span> in patients with <span class="disease" id="16131448-0-78-86">melanoma</span>: results of a phase II trial.